Bellevue Group Ag Crispr Therapeutics Ag Transaction History

Bellevue Group Ag

$5.93 Billion
Q3 2024

A detailed history of Bellevue Group Ag transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Bellevue Group Ag holds 610,000 shares of CRSP stock, worth $25 Million. This represents 0.48% of its overall portfolio holdings.

Number of Shares

610,000

Previous 617,649 1.24%

Holding current value

$25 Million

Previous $33.4 Million 14.08%

% of portfolio

0.48%

Previous 0.56%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$44.62 - $62.75 $341,298 - $479,974	-7,649 Reduced 1.24%	610,000 $28.7 Million
Q2 2024 Aug 14, 2024	SELL	$51.17 - $68.18 $117,742 - $156,882	-2,301 Reduced 0.37%	617,649 $33.4 Million
Q1 2024 May 15, 2024	SELL	$60.67 - $89.12 $17 Million - $25 Million	-280,450 Reduced 31.15%	619,950 $42.3 Million
Q4 2023 Feb 14, 2024	BUY	$38.62 - $72.18 $77,240 - $144,360	2,000 Added 0.22%	900,400 $56.4 Million
Q3 2023 Nov 14, 2023	SELL	$45.39 - $59.0 $40,851 - $53,100	-900 Reduced 0.1%	898,400 $40.8 Million
Q2 2023 Aug 14, 2023	SELL	$43.47 - $67.77 $21,735 - $33,885	-500 Reduced 0.06%	899,300 $50.5 Million
Q1 2023 May 15, 2023	SELL	$41.0 - $56.12 $488,105 - $668,108	-11,905 Reduced 1.31%	899,800 $40.7 Million
Q4 2022 Feb 14, 2023	SELL	$39.19 - $65.67 $650,554 - $1.09 Million	-16,600 Reduced 1.79%	911,705 $37.1 Million
Q3 2022 Nov 14, 2022	BUY	$61.1 - $83.78 $384,930 - $527,814	6,300 Added 0.68%	928,305 $60.7 Million
Q2 2022 Aug 11, 2022	SELL	$43.23 - $73.83 $211,826 - $361,767	-4,900 Reduced 0.53%	922,005 $56 Million
Q1 2022 May 13, 2022	SELL	$53.19 - $79.24 $2.54 Million - $3.79 Million	-47,779 Reduced 4.9%	926,905 $58.2 Million
Q3 2021 Nov 12, 2021	BUY	$110.2 - $156.64 $859,560 - $1.22 Million	7,800 Added 0.81%	974,684 $109 Million
Q2 2021 Aug 12, 2021	SELL	$100.84 - $161.89 $1.16 Million - $1.86 Million	-11,500 Reduced 1.18%	966,884 $157 Million
Q1 2021 May 12, 2021	BUY	$110.72 - $210.04 $7.61 Million - $14.4 Million	68,700 Added 7.55%	978,384 $119 Million
Q4 2020 Feb 16, 2021	SELL	$79.67 - $173.23 $3.15 Million - $6.86 Million	-39,578 Reduced 4.17%	909,684 $139 Million
Q3 2020 Nov 16, 2020	BUY	$78.5 - $100.64 $11.7 Million - $15 Million	148,800 Added 18.59%	949,262 $79.4 Million
Q1 2020 May 14, 2020	BUY	$33.68 - $62.53 $2.36 Million - $4.38 Million	70,000 Added 9.58%	800,462 $33.9 Million
Q4 2019 Feb 14, 2020	SELL	$36.68 - $73.13 $3.91 Million - $7.8 Million	-106,700 Reduced 12.75%	730,462 $44.5 Million
Q3 2019 Nov 14, 2019	BUY	$40.99 - $52.56 $1.09 Million - $1.4 Million	26,700 Added 3.29%	837,162 $34.3 Million
Q2 2019 Aug 14, 2019	BUY	$35.45 - $48.2 $28.7 Million - $39.1 Million	810,462 New	810,462 $38.2 Million

Others Institutions Holding CRSP

# of Institutions

490

Shares Held

58M

Call Options Held

1.1M

Put Options Held

1.9M

View Full List

About CRISPR Therapeutics AG

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.19B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

More about CRSP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Bellevue Group Ag with notifications on news.

Account

Bellevue Group Ag Crispr Therapeutics Ag Transaction History